New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
09:27 EDTSNTASynta Pharmaceuticals weakness overdone, says Roth Capital
Roth Capital notes that Synta announced positive interim data from a trial of its ganetespib monotherapy for breast cancer, and the firm thinks the stock has been overly beaten down. The firm keeps a $27 price target and Buy rating on the shares.
News For SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
07:09 EDTSNTASynta Pharmaceuticals announces initiation of I-SPY 2 trial of Ganetespib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use